Cheniere Energy vs Liquidia Corporation Common Stock — how do they compare? Cheniere Energy trades at $280.53 (market cap $57.77B), while Liquidia Corporation Common Stock trades at $34 (market cap $3.04B). The key difference: Cheniere Energy is far larger — about 19× Liquidia Corporation Common Stock's market cap, and Cheniere Energy pays a 0.79% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and Liquidia Corporation Common Stock for 0 Days on average.
| LNG | LQDA | |
|---|---|---|
Market Cap | $57.77B | $3.04B |
Volume | 1,602,545 | 21,111,778 |
Sector | Energy | Health |
52-Week High | $296.91 | $91.03 |
52-Week Low | $188.83 | $22.02 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $83.22B | $2.94B |
Dividend Yield | 0.79% | — |
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →